MedElevator
Войти в исследования Cancer diagnosis & prognosis · 2025
Palatal Solitary Plasmacytoma: A Case Report on Post-radiotherapy Challenges.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamashita Mayuko, Kondo Yoshihiko, Endo Shinya, Nishimura Nao, Kawano Yawara, Hirosue Akiyuki, Yoshida Ryoji, Nakayama Hideki, Komohara Yoshihiro
Аннотация
BACKGROUND/AIM: Plasmacytomas are neoplastic proliferations of plasma cells, usually presenting as solitary lesions distinct from multiple myeloma (MM). Solitary plasmacytomas in the oral cavity and head and neck are very rare, with limited data on clinical course and treatment response.
CASE REPORT: A 78-year-old woman presented with a solitary plasmacytoma on the palate. Imaging ruled out bone or systemic involvement. Pathology showed positivity for CD138, lambda light chain, CD79a, MUM1, Ki-67 (10-15%), and amyloid deposits. Although the patient received definitive radiation therapy (50 Gy/25 fractions), residual disease remained. At the patient's request, six cycles of systemic chemotherapy with daratumumab, lenalidomide, and dexamethasone (DRd) were administered, leading to further shrinkage without complete response.
CONCLUSION: This rare case of solitary plasmacytoma showed residual disease post definitive radiotherapy. In those residual tumors, close long-term monitoring is crucial.
CASE REPORT: A 78-year-old woman presented with a solitary plasmacytoma on the palate. Imaging ruled out bone or systemic involvement. Pathology showed positivity for CD138, lambda light chain, CD79a, MUM1, Ki-67 (10-15%), and amyloid deposits. Although the patient received definitive radiation therapy (50 Gy/25 fractions), residual disease remained. At the patient's request, six cycles of systemic chemotherapy with daratumumab, lenalidomide, and dexamethasone (DRd) were administered, leading to further shrinkage without complete response.
CONCLUSION: This rare case of solitary plasmacytoma showed residual disease post definitive radiotherapy. In those residual tumors, close long-term monitoring is crucial.